article thumbnail

Capturing COVID: Biopharma through the lens during the pandemic

Fierce Pharma

A few months ago, Fierce Pharma asked employees working in the biopharma industry to use photographs to tell their stories during the pandemic. After wreaking havoc on a pandemic level for more than three years, COVID-19 has entered its first endemic season. | Now, we’re showcasing those precious memories here.

Biopharma 181
article thumbnail

Biopharma staffers exhausted and susceptible to burnout, report says

Fierce Pharma

Biopharma staffers exhausted and susceptible to burnout, report says kdunleavy Wed, 05/24/2023 - 16:52

Biopharma 295
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Embracing Personalization in Biopharma Patient Support Programs

Fierce Pharma

Embracing Personalization in Biopharma Patient Support Programs mteefey Tue, 04/18/2023 - 14:48

Biopharma 237
article thumbnail

FTC, amid biopharma M&A drive, says it will take action against 'sham' patents

Fierce Pharma

Amid the Federal Trade Commission's (FTC's) campaign to bolster scrutiny around large biopharma M&A deals, the agency is now taking a closer look at patent gamesmanship. |

Biopharma 201
article thumbnail

With FTC eyeing biopharma M&A deals, Pfizer refiles paperwork for $43B buyout of Seagen

Fierce Pharma

billion buyout of Horizon Therapeutics has raised concerns that the United States’ antitrust watchdog is tightening the screws on major M&A moves in the biopharma industry. An FTC lawsuit aimed at blocking Amgen’s $27.8 billion buyout o | An FTC lawsuit aimed at blocking Amgen’s $27.8

Biopharma 268
article thumbnail

FTC seeks to block Amgen's $28B Horizon buy in 'broadly negative' move for biopharma M&A: report

Fierce Pharma

FTC seeks to block Amgen's $28B Horizon buy in 'broadly negative' move for biopharma M&A: report aliu Tue, 05/16/2023 - 09:41

Biopharma 296
article thumbnail

Coming and going paid off for biopharma CEOs in 2022

Fierce Pharma

But there was no evidence of the slide in biopharma where pay increases were plentiful. There was a decline in CEO compensation overall in 2022.

Biopharma 182